Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial…

Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA ), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter.“I am very pleased to appoint Geir Christian as our...

In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma…

With rising development costs of pharmaceuticals, delayed approvals, protocol failures, and persistent patient-recruitment challenges, in-silico trial (IST) platforms have become essential tools for accelerating evidence generation. They are now widely adopted by pharmaceutical companies, medical device manufacturers, CROs, and academic research institutions seeking to modernize clinical development and enhance decision-making precision. With rising development costs of pharmaceuticals…

Intratumoral Cancer Therapies Market to Reach USD 630.7 Million by 2033 as…

The growing clinical validation of intratumoral immunotherapies, including oncolytic viruses, adenoviral gene-delivery platforms, STING agonists, and localized immunomodulators, has significantly accelerated the adoption of this treatment approach. These modalities are being actively advanced for advanced melanoma, head and neck cancers, breast tumors, and other hard-to-treat solid tumors and metastatic lesions, where direct tumor injection can enhance local immune activation and improve…

Change of management at NTG Nordic Transport Group A/S

Company announcement no. 11 – 25 27 November 2025 Change of management at NTG Nordic Transport Group A/S Appointment of new Group CFO NTG announces the appointment of Tinneke Torpe as the new Group Chief Financial Officer (“CFO”), effective no later than 1 April 2026. Tinneke brings extensive experience in financial leadership roles, most recently serving as CFO at TP Aerospace Group, where she was responsible for Business Finance, Accounting, IT & Digitalisation, and Legal...

Hair Accessories Market to Reach $57.1 billion, Globally, by 2034 at 8.7% CAGR…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06430 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A06430 Market Introduction The hair accessories market encompasses a wide range of fashion and functional products designed to enhance hairstyling, improve grooming convenience, and complement personal aesthetics. These accessories play a vital role in everyday styling as well as...

K-Beauty Shines as COSRX Snail Mucin Essence Claims No.1 on Amazon UK During…

Its 96% snail mucin formula helps repair the skin barrier, ease dryness and irritation, and revives a radiant glow, all with a lightweight gel texture that absorbs effortlessly. The essence has also become a global social media phenomenon, propelled by millions of TikTok views and compelling user-generated before-and-after content. This blend of clinical performance and viral community proof has cemented its cult status among dermatology enthusiasts, beauty creators, and loyal consumers. Its...

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical…

Previously, Gan & Lee has conducted two phase 3 clinical studies (GRADUAL-1 and GRADUAL-2) of bofanglutide injection for weight management in adults with obesity or overweight. In GRADUAL-2 study, bofanglutide injection is the first GLP-1 RA globally to be evaluated in a head-to-head, parallel-group comparison with semaglutide 2.4 mg (Wegovy®) in Chinese adults with obesity or overweight, with or without type 2 diabetes. These studies are designed to comprehensively assess and confirm the…

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health…

Interim data from the ongoing SERAS-Home_RWD clinical study currently being prepared for publication Interim data from the ongoing SERAS-Home_RWD clinical study currently being prepared for publication BARCELONA, Spainand DÜSSELDORF,Germany , Nov. 27, 2025 /PRNewswire/ --Neuraxpharm Group(Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, andmjn-neuro, a start-up that designs, manufactures...

European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's…

Aceruloplasminemiais an autosomal recessive disorder caused by mutations in the CP gene, leading to a deficiency or absence of Ceruloplasmin, a key plasma protein essential for iron transport. Without treatment, iron accumulates in the brain, liver, and pancreas, causing severe neurological symptoms, diabetes, anemia, and retinal degeneration.Source : Orphanethttps://www.orpha.net/en/disease/detail/48818 EMA's decision highlightsKedrion's role as a science-driven innovator...

Xinhua Silk Road: Exhibition on China's Dehua white porcelain opens in Los…

Addressing the event, Huang Hongjiang, deputy consul general of China in Los Angeles, said Dehua porcelain represents not only China's long-standing cultural traditions but also its refined modern craftsmanship. Addressing the event, Huang Hongjiang, deputy consul general ofChinainLos Angeles, said Dehua porcelain represents not onlyChina'slong-standing cultural traditions but also its refined modern craftsmanship. Huang saidChina'supcoming 15th Five-Year Plan offers broad...

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares and a second tranche of 1,770,226 new shares ("Tranche 2"), and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform. Radforsk Investeringsstiftelse…

71,498 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 NOVEMBER 2025 at 9.00 EET 71,498 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 71,498 A shares have been converted into 71,498 B shares. The conversion has been entered into the Trade Register on 27 November 2025.The total number of shares in Orion Corporation is 141,134,278...

Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M

Preliminary pharmacokinetic and safety evaluations of LPT-CBD in minipigs, provide encouraging support for Innocan's regulatory strategy to advance LPT-CBD IND-enabling studies in alignment with FDA standards. Preliminary pharmacokinetic and safety evaluations of LPT-CBD in minipigs, provide encouraging support for Innocan's regulatory strategy to advance LPT-CBD IND-enabling studies in alignment with FDA standards. In addition, meaningful pre-clinical data provides clinically translatable...

Aphranel Debuts at SAAM 2025, Spotlighting Original CaHA and the MagiCConcept…

SAAM 2025, one of the Middle East's most influential aesthetic medicine conferences, drew more than 2,500 participants from the United States, Germany, Switzerland, the Middle East, and other regions, spanning aesthetic dermatology, laser therapies, plastic surgery, and medical aesthetics. Aphranel's presence alongside Chinese experts highlights the growing integration of China's aesthetic technologies and treatment concepts into global practice. SAAM 2025, one of theMiddle East'smost...

Elanco executive appointed as Neurizon's Board Observer

Ms Conway is a seasoned healthcare professional with more than two decades of experience across the animal health and healthcare industries. She joined Elanco in 2020 as Global Head of Business Development, following an extensive investment banking career with Macquarie Bank and Bank of America Merrill Lynch, where she held senior roles across Sydney, London and New York. Ms Conway is a seasoned healthcare professional with more than two decades of experience across the animal health and...

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial…

Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period…

Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference

GENFIT Announces Appointment of new Chief Medical Officer

Cosmetic Surgery Market is expected to generate a revenue of USD 71.33 Billion…

Pet DNA Testing Market to Reach $960.7 Million, Globally, by 2034 at 9.3% CAGR…

Lateral Flow Assays Market to Soar to $17.44 Billion by 2033 Amid Robust 6.98%…

Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease…

Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders…

xTool Launches F2 Ultra UV, a True Glass Master and Ultra-Precise Laser

In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma…

Intratumoral Cancer Therapies Market to Reach USD 630.7 Million by 2033 as…

Change of management at NTG Nordic Transport Group A/S

Hair Accessories Market to Reach $57.1 billion, Globally, by 2034 at 8.7% CAGR…

K-Beauty Shines as COSRX Snail Mucin Essence Claims No.1 on Amazon UK During…

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical…

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health…

European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's…

Xinhua Silk Road: Exhibition on China's Dehua white porcelain opens in Los…

Zelluna ASA: Disclosure of large shareholding

71,498 Orion Corporation A shares converted into B shares

Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M

Aphranel Debuts at SAAM 2025, Spotlighting Original CaHA and the MagiCConcept…

Elanco executive appointed as Neurizon's Board Observer